Skip Navigation



International Immunology Advance Access published online on February 28, 2008
International Immunology, doi:10.1093/intimm/dxn016
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
20/4/577    most recent
dxn016v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Rojo, J. M.
Right arrow Articles by Portolés, P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rojo, J. M.
Right arrow Articles by Portolés, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Japanese Society for Immunology. 2008. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

CD4+ICOS+ T lymphocytes inhibit T cell activation ‘in vitro’ and attenuate autoimmune encephalitis ‘in vivo’

Jose M. Rojo1, Eliana Pini2, Gloria Ojeda2, Raquel Bello1, Chen Dong3, Richard A. Flavell4,5, Umberto Dianzani6 and Pilar Portolés2

1 Departamento de Inmunología, Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas, Ramiro de Maeztu 9, E-28040 Madrid, Spain
2 Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, E-28220 Madrid, Spain
3 Department of Immunology, M. D. Anderson Cancer Centre, 7455 Fannin, Unit 902, Houston, TX 77030-1903, USA
4 Howard Hughes Medical Institute
5 Department of Immunobiology, Yale University School of Medicine, 310 Cedar Street, New Haven, CT 06520, USA
6 Department of Medical Sciences, ‘A. Avogadro’ University of Eastern Piedmont, Via Solaroli 17, I-28100 Novara, Italy

Correspondence to: Correspondence to: J. M. Rojo; E-mail: jmrojo{at}cib.csic.es

The inducible co-stimulator (ICOS, CD278) is essential to the efficient development of normal and pathological immune reactions. Since ICOS-deficient mice have enhanced susceptibility to experimental allergic encephalomyelitis (EAE), we have functionally analyzed a CD4+ICOS+ population comprising 6–15% of all CD4+ T cells in secondary lymphoid organs of unmanipulated wild-type mice and checked for their ability to suppress EAE. In C57BL/6 mice, CD4+ICOS+ cells were a major source of cytokines including IFN-{gamma}, IL-2, IL-4, IL-10 or IL-17A. Upon activation, these cells showed preferentially enhanced production of IL-4 or IL-10 but inhibited IFN-{gamma} production. In contrast, CD4+ICOS– cells mainly produced IFN-{gamma}. Interestingly, CD4+ICOS+ cells partially suppressed the proliferation of CD4+ICOS– or CD4+CD25– lymphocytes ‘in vitro’ by an IL-10-dependent mechanism. Furthermore, CD4+ICOS+ activated and expanded under appropriate conditions yielded a population enriched in cells producing IL-10 and Th2 cytokines that also suppressed the proliferation of CD4+CD25– lymphocytes. CD4+ICOS+ cells, before or after expansion in vitro, reduced the severity of EAE when transferred to ICOS-deficient mice. In the same EAE model, lymph node cells from ICOS-deficient mice receiving ICOS+ cells showed reduced IL-17A production and enhanced IL-10 secretion upon antigen activation in vitro. Thus, naturally occurring CD4+ICOS+ cells, expanded or not in vitro, are functionally relevant cells able of protecting ICOS-deficient mice from severe EAE.

Keywords: CD278, EAE, ICOS, inducible co-stimulator, regulatory T cells

Received 17 May 2007, revised 12 December 2007, accepted 23 January 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.